| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 安科生物(香港)有限公司 | 4,245,600 | 2.75% | 1.30% | 6 months |
| Derivatives China Alpha Fund SPC(为及代表Derivatives China Fundamental Fund SP行事) | 1,895,300 | 1.23% | 0.58% | 6 months |
| 国泰君安证券投资(香港)有限公司(有关中和场外掉期) | 1,463,200 | 3.86% | 0.45% | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The retail tranche saw an overwhelming 3,526.34x oversubscription, signaling extreme investor enthusiasm for this 18A biotech listing. With a hit rate of just 13.41% and reallocation triggered, the overall subscription was heavily congested, reflecting strong demand despite the high risk profile of pre-revenue biotech firms. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
A notable tier anomaly: A-tail applicants needed 100,000 lots for an expected allocation of just 1 lot, while B-head applicants required double that (200,000 lots) for the same 1-lot expected return. This creates high capital inefficiency at both tiers, with B-head incurring significantly higher margin interest costs for identical share allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Broker fee structures vary; actual costs may differ.)
Demographic data for this IPO is not available in the source filings — mainland participation rate, gender split, and regional concentration are all reported as zero or null. Without such breakdown, it’s impossible to comment on the investor profile, though high oversubscription often correlates with strong mainland interest in HK biotech offerings. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Data may contain errors or omissions from source documents — verify against official HKEX filings.)
This page shows allotment analysis for Bao Pharma-B (02659): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

